These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8476993)

  • 21. Site-specific activation of the alternative pathway of complement. Synthesis of a hybrid molecule consisting of antibody and cobra venom factor.
    Parker CJ; White VF; Falk RJ
    Complement; 1986; 3(4):223-35. PubMed ID: 3643079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The low C5 convertase activity of the C4A6 allotype of human complement component C4.
    Kinoshita T; Dodds AW; Law SK; Inoue K
    Biochem J; 1989 Aug; 261(3):743-8. PubMed ID: 2803239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway.
    Fearon DT
    Proc Natl Acad Sci U S A; 1978 Apr; 75(4):1971-5. PubMed ID: 273923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Role of immunoglobulins in the activation of complement].
    Colomb MG; Bensa JC
    Presse Med; 1983 Nov; 12(41):2577-82. PubMed ID: 6228793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3.
    Pangburn MK; Müller-Eberhard HJ
    Ann N Y Acad Sci; 1983; 421():291-8. PubMed ID: 6586103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome.
    Sartz L; Olin AI; Kristoffersson AC; Ståhl AL; Johansson ME; Westman K; Fremeaux-Bacchi V; Nilsson-Ekdahl K; Karpman D
    J Immunol; 2012 Feb; 188(4):2030-7. PubMed ID: 22250080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.
    Farries TC; Lachmann PJ; Harrison RA
    Biochem J; 1988 May; 252(1):47-54. PubMed ID: 3421908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreased material-activation of the complement system using low-energy plasma polymerized poly(vinyl pyrrolidone) coatings.
    Andersen TE; Palarasah Y; Skjødt MO; Ogaki R; Benter M; Alei M; Kolmos HJ; Koch C; Kingshott P
    Biomaterials; 2011 Jul; 32(20):4481-8. PubMed ID: 21453967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The tick-over theory revisited: is C3 a contact-activated protein?
    Nilsson B; Nilsson Ekdahl K
    Immunobiology; 2012 Nov; 217(11):1106-10. PubMed ID: 22964236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Testing the Activity of Complement Convertases in Serum/Plasma for Diagnosis of C4NeF-Mediated C3 Glomerulonephritis.
    Blom AM; Corvillo F; Magda M; Stasiłojć G; Nozal P; Pérez-Valdivia MÁ; Cabello-Chaves V; Rodríguez de Córdoba S; López-Trascasa M; Okrój M
    J Clin Immunol; 2016 Jul; 36(5):517-27. PubMed ID: 27146825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional assessment of mouse complement pathway activities and quantification of C3b/C3c/iC3b in an experimental model of mouse renal ischaemia/reperfusion injury.
    Kotimaa JP; van Werkhoven MB; O'Flynn J; Klar-Mohamad N; van Groningen J; Schilders G; Rutjes H; Daha MR; Seelen MA; van Kooten C
    J Immunol Methods; 2015 Apr; 419():25-34. PubMed ID: 25733354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b.
    Kazatchkine MD; Fearon DT; Silbert JE; Austen KF
    J Exp Med; 1979 Nov; 150(5):1202-15. PubMed ID: 501288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Control of C3b and C5b deposition by CD46 (membrane cofactor protein) after alternative but not classical complement activation.
    Devaux P; Christiansen D; Fontaine M; Gerlier D
    Eur J Immunol; 1999 Mar; 29(3):815-22. PubMed ID: 10092084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complement activation and adsorption of protein fragments by functionalized polymer surfaces in human serum.
    Montdargent B; Toufik J; Carreno MP; Labarre D; Jozefowicz M
    Biomaterials; 1992; 13(9):571-6. PubMed ID: 1382638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On the binding of complement to solid artificial surfaces in vitro.
    Wetterö J; Askendal A; Bengtsson T; Tengvall P
    Biomaterials; 2002 Feb; 23(4):981-91. PubMed ID: 11791932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blood protein interactions with titanium surfaces.
    Wälivaara B; Askendal A; Lundström I; Tengvall P
    J Biomater Sci Polym Ed; 1996; 8(1):41-8. PubMed ID: 8933289
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of complement-protein-C3b density on the binding of complement factor H to surface-bound C3b.
    Koistinen V
    Biochem J; 1991 Nov; 280 ( Pt 1)(Pt 1):255-9. PubMed ID: 1835839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
    Medof ME; Kinoshita T; Nussenzweig V
    J Exp Med; 1984 Nov; 160(5):1558-78. PubMed ID: 6238120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
    Pangburn MK; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1978 May; 75(5):2416-20. PubMed ID: 276881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.